Report reveals plausibility that COVID-19 leaked from Wuhan lab

A new report reveals that it’s plausible the COVID-19 leaked from a Wuhan lab, giving other calls for investigation into the origin of the virus new life.

The report, from Lawrence Livermore National Laboratory in California was prepared in May 2020 and was used by the State Department to investigate the pandemic’s origins, The Wall Street Journal reported. 

The report adds to other calls for a deeper investigation into the origin of COVID-19. Coronaviruses often come from bats, camels and cats, and jump to humans upon evolving, according to the National Foundation for Infectious Disease (NFID).

While the report is more than a year old, it’s attracting fresh eyes since the Biden administration has called for further investigations into how the pandemic started. U.S. investigations have focused on “whether the coronavirus came from human contact with an infected animal or from a laboratory accident,” the WSJ reported.

Calls for more investigations heightened after it was revealed researchers from a Wuhan lab became seriously ill and were hospitalized in late 2019.

“What the government didn’t do in the early days and still hasn’t done is given us the transparency we need,” Secretary of State Antony Blinken said in a recent interview with Axios.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.